The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1308
Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex – Takeda), a delayed-release formulation of the R-enantiomer of lansoprazole (Prevacid – Takeda), for treating and maintaining healing of erosive esophagitis and for treatment of heartburn associated with non-erosive gastro-esophageal reflux disease (GERD). Both enantiomers of lansoprazole are active, but the R-enantiomer is longer acting.1 Lansoprazole is expected to become available generically later this year.2

FORMULATIONKapidex is formulated as capsules containing dexlansoprazole in 2 types of enteric-coated granules that are soluble at 2 different pHs.The drug is designed to dissolve first in the proximal and then in the distal small intestine.

PHARMACOKINETICS — With a dose of 60 mg, serum concentrations of dexlansoprazole first reach a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
Article code: 1308a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian